A study by the Mildred Scheel Early Career Center group led by Dr. Mohamed Elgendy at the TUD Faculty of Medicine provides fundamental insights into cancer biology. Published in Nature Communications, the study shows for the first time that the protein MCL1 not only inhibits programmed cell death, but also plays a central role in tumor metabolism.
The researchers have succeeded in tracing two classic hallmarks of cancer—the evasion of apoptosis (a form of programmed cell death) and the dysregulation of energy metabolism—back to a common molecular mechanism.
The study focuses on the protein MCL1, which is strongly overexpressed in many tumor types and has previously been considered primarily an anti-apoptotic factor of the Bcl-2 protein family.









